Eli Lilly and Company (NYSE:LLY) Holdings Reduced by Teewinot Capital Advisers L.L.C.

Teewinot Capital Advisers L.L.C. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 87,058 shares of the company’s stock after selling 1,048 shares during the period. Eli Lilly and Company makes up approximately 7.8% of Teewinot Capital Advisers L.L.C.’s portfolio, making the stock its 5th largest position. Teewinot Capital Advisers L.L.C.’s holdings in Eli Lilly and Company were worth $78,821,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $36,000. Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $37,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 364,810 shares of company stock valued at $339,366,198. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on LLY shares. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Bank of America boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Price Performance

NYSE LLY opened at $877.79 on Monday. The stock’s 50-day moving average is $896.10 and its two-hundred day moving average is $844.12. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The firm has a market cap of $834.26 billion, a P/E ratio of 129.28, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.